You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Introducing Cervarix

Cervarix is a vaccine for use from the age of 9 years for the prevention of pre-malignant genital lesions and cervical cancer causally related to certain oncogenic human papilloma virus (HPV) types.1

Cervical Cancer

References:

  1. Cervarix IPI Version number: GDS024/ IPI019 / Date of issue: 02/Mar/15 2015 GSK group of companies
  2. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89–99.
  3. GLOBOCAN. Cervical Cancer Incidence and Mortality Worldwide in 2012: Cancer Fact Sheet. Available at: http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp. Last accessed February 2017.
  4. American Cancer Society - Cervical cancer? Available at: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer. Last accessed February 2017.

Cervarix is a registered trademark of GlaxoSmithKline group of companies.